February 4, 2012
| Bio-IT World > Welcome to Bio·IT World


Welcome to Bio·IT World


By Morris R. Levitt 
President and CEO

Morris R. Levitt, Ph.D. I wonder if anyone back in the 1950s foresaw that the developments flowing from the elucidation of the double helix structure of DNA and the invention of the transistor would ultimately converge as they have so dramatically in the past decade. In a way, however, the convergence of life science and computer technology was preordained once it was known that genetic information and related biological processes are digitally encoded in the sequence of paired bases comprising the genome of any organism.

Certainly the field called "computational biology" in the 1980s and early '90s reflected the connection between bioscience and information technology (IT). With the advent of more advanced forms of bioinformatics, and its recent spectacular successes culminating with the sequencing of the human genome, we are now well into the era of explicit convergence of the disciplines of information technology and life sciences.

But the convergence of IT and life sciences has created a new set of challenges and needs. The principal issues include: the need for further advances in basic bioscience; collaboration and communication across IT and biosciences; data standardization; technology selection; organizational development and management; and the evolution of successful business models.

The primary mission of Bio·IT World is to make our own modest contribution to enhancing the productivity of life science research, development, and applications and the business success of our constituencies in the biotech and pharmaceutical industries. We aim to do that through the unique focus of Bio·IT World's content on the interrelationship of bioscience and IT, as well as through other specialized publications, conferences, and Web-based information that we will provide to the Bio-IT community.

We are strongly motivated by the knowledge that the stakes are high but the best is yet to come. The life sciences market for IT infrastructure products and services (including bioinformatics) is already at an annualized level of $10 billion and is projected by our sister company, International Data Corporation, to grow to $30 billion by 2005. Choosing the most effective IT tools from the growing flood of options is a daunting challenge that can make the difference between success and failure for life science companies.

On the research front, hundreds of genes associated with specific disorders have already been identified, but we have a long way to go in unraveling protein-protein interactions and developing the scientific and practical basis for individualized medical treatments. We also have a long way to go in increasing the efficiency of the drug discovery and development process, which is largely driven by advances in IT systems and their improved applications in bioscience and biotechnology.

We can only imagine what will emerge from the next 50 years of IT and life science developments, and the opportunities that will be created by you, our readers. Bio·IT World is proud to join the scientific and business communities creating that exciting future.* 





White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .